文献速递前列腺癌

多模式治疗范式加速早期转移性前列腺癌药物评价的初步研究

A Pilot Study of a Multimodal Treatment Paradigm to Accelerate Drug Evaluations in Early-stage Metastatic Prostate Cancer.
PubMed 文献 · Urology · 2016-11-22

本研究纳入20例初诊为寡转移M1a或M1b的前列腺癌患者,采用雄激素剥夺、根治性前列腺切除加盆腔淋巴结清扫(临床阳性腹膜后淋巴结者行腹膜后淋巴结清扫)及立体定向体部放疗的多模式序贯治疗。95%患者达到PSA不可测,20%(95%CI 3%-38%)在睾酮恢复后PSA不可测,持续5、6、27+和46+个月。

要点

  • 20例初诊寡转移M1a或M1b前列腺癌患者接受多模式序贯治疗,95%达到PSA不可测。
  • 雄激素剥夺单独使25%患者PSA不可测,手术和放疗分别额外贡献50%和20%。
  • 20%(95%CI 3%-38%)达到主要终点(睾酮恢复后PSA不可测),持续5至46+个月。

核心结论

  • 序贯应用的多模式治疗策略可在部分初诊转移性前列腺癌患者中消除可检测疾病。
  • 在评估早期转移性疾病新方法时,应考虑以睾酮恢复后PSA不可测作为终点,以快速确定大规模试验的优先次序,并将治疗范式从姑息转向治愈。

研究设计与样本

  • 初步研究,纳入20例初诊为寡转移M1a(盆腔外淋巴结转移)或M1b(骨转移)且单模式治疗无法治愈的前列腺癌患者。
  • 多模式治疗包括雄激素剥夺、根治性前列腺切除加盆腔淋巴结清扫(临床阳性腹膜后淋巴结者行腹膜后淋巴结清扫)及对骨病灶或原发灶的立体定向体部放疗。
  • 主要终点为睾酮恢复后PSA不可测。

主要发现

  • 95%的患者在多模式治疗后达到PSA不可测。
  • 雄激素剥夺单独使25%患者PSA不可测,手术后额外50%、放疗后额外20%达到PSA不可测。
  • 20%(95%CI 3%-38%)达到主要终点,持续5、6、27+和46+个月。
  • 所有达到主要终点的患者初诊时均分类为M1b疾病。

临床怎么用

  • 作者认为,序贯多模式治疗策略可在部分初诊转移性前列腺癌患者中消除可检测疾病。
  • 作者提出,在评估早期转移性疾病新方法时,应考虑以睾酮恢复后PSA不可测作为终点,以快速确定大规模试验的优先次序,并将治疗范式从姑息转向治愈。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To evaluate a multimodal strategy aimed at treating all sites of disease that provides a rapid readout of success or failure in men presenting with non-castrate metastatic prostate cancers that are incurable with single modality therapy. MATERIALS AND METHODS: Twenty selected men with oligometastatic M1a (extrapelvic nodal disease) or M1b (bone disease) at diagnosis were treated using a multimodal approach that included androgen deprivation, radical prostatectomy plus pelvic lymphadenectomy (retroperitoneal lymphadenectomy in the presence of clinically positive retroperitoneal nodes), and stereotactic body radiotherapy to osseous disease or the primary site. Outcomes of each treatment were assessed sequentially. Androgen deprivation was discontinued in responding patients. The primary end point was an undetectable prostate-specific antigen (PSA) after testosterone recovery. The goal was to eliminate all detectable disease. RESULTS: Each treatment modality contributed to the outcome: 95% of the cohort achieved an undetectable PSA with multimodal treatment, including 25% of patients after androgen deprivation alone and an additional 50% and 20% after surgery and radiotherapy, respectively. Overall, 20% of patients (95% confidence interval: 3%-38%) achieved the primary end point, which persisted for 5, 6, 27+ , and 46+ months. All patients meeting the primary end point had been classified with M1b disease at presentation. CONCLUSION: A sequentially applied multimodal treatment strategy can eliminate detectable disease in selected patients with metastatic spread at diagnosis. The end point of undetectable PSA after testosterone recovery should be considered when evaluating new approaches to rapidly set priorities for large-scale testing in early metastatic disease states and to shift the paradigm from palliation to cure.

来源:Urology,查看原文。版权归原作者所有。

引用

  1. O'Shaughnessy MJ, McBride SM, Vargas HA, et al. A Pilot Study of a Multimodal Treatment Paradigm to Accelerate Drug Evaluations in Early-stage Metastatic Prostate Cancer. Urology. 2016. PMID: 27888148. doi:10.1016/j.urology.2016.10.044

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。